BioAtla Q1 net loss $23.2M, cash $80.6M; positive Phase 2 data for ozuriftamab vedotin and evalstotug

BioAtla, Inc.

2024-Q1 EPS reported -$0.48

Net loss $23.2M in Q1 2024 vs $27.5M in Q1 2023; cash $80.6M as of March 31, 2024.
Ozuriftamab vedotin in SCCHN: 11 total responses (5 confirmed incl. 1 CR), 86% DCR; FDA meeting for potential registrational trial expected 2H 2024.
Evalstotug: DLT clearance at 1 gram in 2Q 2024; Phase 2 monotherapy data 2Q 2024; FDA meeting for BRAF-mutated melanoma registrational trial in 2H 2024.
Mecbotamab vedotin in UPS: initial 20 patients enrolled; FDA meeting for remaining trial portion 2H 2024.
CAB-Nectin4-ADC (BA3361) received FDA IND clearance in May 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BioAtla, Inc. reported financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 14, 2024, BioAtla, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024 and provided an update on its ongoing clinical programs.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

BioAtla, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-059508

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.